Context Therapeutics

Context Therapeutics to Present Clinical Data on ONA-XR in Breast Cancer at 2021 San Antonio Breast Cancer Symposium

PHILADELPHIA, PA  — Context Therapeutics Inc. (Nasdaq: CNTX) announced clinical data on onapristone extended release (ONA-XR) will be presented at the 2021 San Antonio Breast Cancer Symposium (SABCS) taking place …

Context Therapeutics to Present Clinical Data on ONA-XR in Breast Cancer at 2021 San Antonio Breast Cancer Symposium Read More

cancer

Context Therapeutics, Wisconsin Oncology Network Announce First Patient Dosed in Phase 2 Trial of ONA-XR in Metastatic Breast Cancer

PHILADELPHIA, PA — Context Therapeutics Inc. (Nasdaq: CNTX) and Wisconsin Oncology Network (WON) announced the first patient has recently been dosed in the Phase 2 Trial of OnapriStone in CoMbInation …

Context Therapeutics, Wisconsin Oncology Network Announce First Patient Dosed in Phase 2 Trial of ONA-XR in Metastatic Breast Cancer Read More